RespireRx Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RespireRx Pharmaceuticals Inc.
After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?
A high profile panel including the WHO's chief scientist and ministers of Norway and South Africa discussed critical dimensions pertaining to coronavirus vaccines and risks of a “pandemic within a pandemic” with the emergence of SARS-CoV-2 variants. Funding gaps at the ACT Accelerator and extending the shelf life of vaccines were also deliberated.
The global market for arthroscopy products and sports medicine implants is expected to reach $6.3bn by 2025, a CAGR of 1.9% from $5.7bn in 2020. The growth is driven partly by rising arthroscopy procedure volumes, expanding indications for joint repair, and patient preference for minimally invasive procedures. COVID-19 and downward pressures on device prices are among the growth barriers.
The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?
- Other Names / Subsidiaries
- Cortex Pharmaceuticals, Inc.
- Pier Pharmaceuticals, Inc.